For U.S. Healthcare Professionals Only
Important Safety Information  |   Prescribing Information  |   Patients  |   Healthcare Professionals For U.S. Healthcare Professionals Only

Important Safety Information: SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported for both SYNVISC and Synvisc-One. View More

What is Synvisc-One?

Synvisc-One is an injection that supplements the fluid in the knee to help lubricate and cushion the joint, and can provide up to six months of osteoarthritis knee pain relief.

When should a patient consider Synvisc-One?

Synvisc-One is for people with knee osteoarthritis who have not received enough pain relief from diet, exercise and over-the-counter pain medication. If your patients have tried these options and are still feeling knee pain, tell them to ask their doctor if Synvisc-One could help.

How is Synvisc-One given?

Synvisc-One is a single-dose treatment that is injected directly into the knee by a doctor, usually a specialist trained in treating knee osteoarthritis, such as an orthopaedic surgeon or rheumatologist.

Is Synvisc-One covered by insurance?

Synvisc-One is covered by Medicare and most insurance plans.

What are the side effects of Synvisc-One?

The most common side effects are pain, swelling, heat, redness and/or fluid build-up around the knee. In a medical study less than 6% of patients experienced these side effects, which were generally mild and did not last long.

What is the procedure like?

The injection takes a few minutes and can be done in a doctor's office. To watch a video of a real patient's injection, click here.

Will the injection hurt?

A doctor will likely apply a numbing agent before your Synvisc-One injection.

What happens after the injection?

It is recommended that patients avoid strenuous activities (for example, high-impact sports such as tennis or jogging) or prolonged weight-bearing activities for approximately 48 hours following the injection. A patient should consult their doctor regarding the appropriate time to resume these activities.

When will a patient start to feel pain relief?

Everyone responds differently, but in a medical study of 253 patients with knee osteoarthritis, many experienced pain relief starting one month after the injection of Synvisc-One.

How long will a patient experience knee pain relief?

Although all patients respond differently, their osteoarthritis knee pain relief can last up to six months.

Can a patient receive Synvisc-One treatment more than once?

Yes, Synvisc-One can be repeated safely. In a medical study involving 160 patients, 77 received a second injection of Synvisc-One. When a patient's osteoarthritis knee pain returns, tell them to talk to their doctor to see if an additional treatment of Synvisc-One is right for them.

Can both a patient's knees be treated with Synvisc-One?

Yes. A patient can receive treatment in both knees at the same time or at different times. Tell them to ask their doctor to find out what is best for them.

What is Synvisc-One made from?

The injection contains a gel-like mixture made from a substance called hyaluronan (pronounced hy-al-u-ROE-nan) that comes from chicken combs. Hyaluronan is a natural substance found in the body and is present in very high amounts in joints. The body's own hyaluronan acts like a lubricant and a shock absorber in the joint and is needed for the joint to work properly.

How is Synvisc-One different from SYNVISC® (hylan G-F 20)?

Synvisc-One is the same formulation as SYNVISC. The only difference is that Synvisc-One is provided with one injection, compared to the three injections required for SYNVISC. Both treatments can provide up to six months of osteoarthritis knee pain relief.

Indication

SYNVISC® (hylan G-F 20) and Synvisc‑One® (hylan G-F 20) are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen.

Important Safety Information

SYNVISC and Synvisc‑One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported for both SYNVISC and Synvisc‑One.

Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Do not inject SYNVISC or Synvisc‑One extraarticularly, into the synovial tissues, into the fat pad or joint capsule, or intravascularly.

The safety and efficacy of Synvisc‑One in locations other than the knee, or for conditions other than osteoarthritis, or in combination with other intra-articular injectables, or in severely inflamed knee joints have not been established. Use caution when injecting SYNVISC or Synvisc‑One in patients allergic to avian proteins, feathers, or egg products; who have evidence of lymphatic or venous stasis in the leg to be treated; or who have severe inflammation in the knee to be treated. Remove any synovial fluid or effusion before injecting SYNVISC or Synvisc‑One. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC and Synvisc‑One have not been established in children (≤21years old) or in pregnant or lactating women. Patients should be advised to avoid strenuous or prolonged weight-bearing activities for approximately 48 hours after treatment.

For SYNVISC
In clinical trials, the most commonly reported adverse events were transient pain, swelling, and or joint effusion in the injected knee. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Full Prescribing Information for SYNVISC

For Synvisc‑One
The most commonly reported adverse events were arthralgia, arthritis, arthropathy, injection site pain, and joint effusion. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc‑One: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Full Prescribing Information for Synvisc‑One